Aleksandra MD - PureTech Health Head Oncology
| PTCHFDelisted Stock | USD 3.13 0.00 0.00% |
Insider
Aleksandra MD is Head Oncology of PureTech Health plc
| Phone | 617 482 2333 |
| Web | https://www.puretechhealth.com |
PureTech Health Management Efficiency
The company has return on total asset (ROA) of (0.1333) % which means that it has lost $0.1333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0152) %, meaning that it generated substantial loss on money invested by shareholders. PureTech Health's management efficiency ratios could be used to measure how well PureTech Health manages its routine affairs as well as how well it operates its assets and liabilities.PureTech Health plc has accumulated 14.26 M in total debt with debt to equity ratio (D/E) of 0.08, which may suggest the company is not taking enough advantage from borrowing. PureTech Health plc has a current ratio of 2.49, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist PureTech Health until it has trouble settling it off, either with new capital or with free cash flow. So, PureTech Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PureTech Health plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PureTech to invest in growth at high rates of return. When we think about PureTech Health's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Alexis AM | Blueprint Medicines Corp | 52 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Gabriel BA | Immix Biopharma | 37 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 52 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
Management Performance
| Return On Equity | -0.0152 | ||||
| Return On Asset | -0.13 |
PureTech Health plc Leadership Team
Elected by the shareholders, the PureTech Health's board of directors comprises two types of representatives: PureTech Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PureTech. The board's role is to monitor PureTech Health's management team and ensure that shareholders' interests are well served. PureTech Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PureTech Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daphne Zohar, Co-Founder, CEO and Executive Director | ||
| David Elmaleh, Co-Founder and Sr. Advisor | ||
| Allison Talbot, Head Relations | ||
| Eric Elenko, Executive Vice President - Science & Technology | ||
| Spencer Ball, Vice President - Talent Acquisition | ||
| Bennett MD, Co-Founder and Non-Executive Director | ||
| Joseph Bolen, Chief Scientific Officer | ||
| Aleksandra MD, Head Oncology | ||
| Dr JD, Sec and President |
PureTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PureTech Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0152 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.73) % | ||||
| Operating Margin | (9.87) % | ||||
| Current Valuation | 654.5 M | ||||
| Shares Outstanding | 278.81 M | ||||
| Shares Owned By Insiders | 15.48 % | ||||
| Shares Owned By Institutions | 72.20 % | ||||
| Price To Earning | 158.00 X | ||||
| Price To Book | 1.61 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in PureTech Pink Sheet
If you are still planning to invest in PureTech Health plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PureTech Health's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |